Evolus, Inc. EOLS R2KR3KPHARMA
Company Overview
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Why Investors Should Care
Revenue has grown at a 39.4% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $297.18M (+11.6% YoY); net profit $-51.64M.
- Trailing 12 Months Year-on-year growth — revenue +21.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 39.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 39.36% |
| 1 Year: | 21.20% |
Stock Price Performance
| 1 Year: | +42.86% |
| 6 Months: | +68.17% |
| 3 Months: | +39.43% |
| 1 Month: | +25.51% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)73.17 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 39.4% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EOLS Evolus, Inc. R2KR3KPHARMA | 9.30 | -17.55 | $614.27M | 0.00% | -21.69% | - | 39.36% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | 0 | 0 | 2.31M | 13.17M | 10.50M | 7.81M | 17.66M | 12.24M | 26.10M | 26.68M | 33.91M | 37.16M | 33.90M | 41.72M | 49.35M | 50.02M | 59.33M | 66.91M | 61.09M | 68.52M | 69.39M | 68.97M | 73.14M | 84.08M |
| Gross Profit | - | - | - | - | 0 | 0 | 0 | 1.65M | 9.45M | 6.28M | 5.86M | 12.81M | - | - | - | - | - | - | - | - | - | 40.50M | 47.07M | 42.10M | 46.66M | 45.32M | 45.84M | 48.90M | 57.18M |
| Operating Income | -3.98M | -2.27M | -2.62M | -6.04M | -16.10M | -11.49M | -25.27M | -36.00M | -25.14M | -17.39M | -18.89M | -8.76M | 8.03M | -15.29M | -19.11M | -15.45M | -21.35M | -17.90M | -12.04M | -15.12M | -13.44M | -8.92M | -7.70M | -15.47M | -15.17M | -10.21M | -11.50M | -6.85M | -4.54M |
| Net Income | -4.00M | -2.30M | -2.63M | -6.16M | -16.43M | -11.83M | -10.97M | -37.57M | -26.98M | -19.73M | -21.12M | -11.46M | 6.40M | -15.60M | -19.43M | -17.50M | -23.47M | -20.28M | -14.79M | -18.14M | -16.92M | -13.11M | -11.35M | -19.17M | -18.89M | -17.14M | -15.74M | -10.67M | -8.05M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -0.59 | -0.63 | -0.34 | 0.16 | -0.31 | -0.35 | -0.31 | -0.42 | -0.36 | -0.26 | -0.32 | -0.30 | -0.22 | -0.18 | -0.30 | -0.30 | -0.27 | -0.24 | -0.16 | -0.12 |
| R&D Expense | 2.65M | 1.36M | 1.47M | 1.68M | 1.65M | 1.98M | 2.35M | 509.00K | 693.00K | 507.00K | 145.00K | 350.00K | 841.00K | 499.00K | 301.00K | 468.00K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | 34.92M | 56.54M | 99.67M | 148.62M | 202.09M | 266.27M | 297.18M |
| Gross Profit | - | 0 | 26.91M | - | - | 89.77M | 137.57M | 182.30M | 197.11M |
| Operating Income | -11.73M | -46.14M | -98.95M | -153.07M | -44.41M | -65.33M | -49.23M | -34.41M | -32.66M |
| Net Income | -4.48M | -46.87M | -90.03M | -163.01M | -46.81M | -74.41M | -61.69M | -50.42M | -51.64M |
| Diluted EPS | - | - | - | -4.83 | -0.94 | -1.33 | -1.08 | -0.81 | -0.80 |
| R&D Expense | 6.69M | 6.49M | 3.97M | 1.72M | 2.06M | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 152.23M | 171.84M | 240.44M | 209.07M | - | 177.98M | 189.00M | 232.57M | 225.87M |
| Current Assets | - | - | - | - | - | - | 100.80M | 112.42M | 151.34M | 142.92M |
| Cash & Equivalents | - | 0 | 93.16M | 109.89M | 102.56M | - | 53.92M | 62.84M | 86.95M | 53.83M |
| Inventory | - | - | - | - | - | - | 18.85M | 11.00M | 12.16M | 26.96M |
| Receivables | - | - | - | - | - | - | 22.45M | 30.53M | 47.68M | 54.70M |
| Total Liabilities | - | 227.78M | 87.46M | 160.99M | 282.03M | - | 159.48M | 209.69M | 227.05M | 248.97M |
| Current Liabilities | - | 212.75M | 5.28M | 24.44M | 180.25M | - | 46.51M | 48.29M | 62.96M | 75.31M |
| Long Term Debt | - | - | 0 | 73.51M | - | - | 71.88M | 120.36M | 121.51M | 146.10M |
| Total Debt | - | - | - | - | - | - | 74.42M | 126.55M | 129.98M | 155.00M |
| Total Equity | -7.11M | -75.54M | 84.38M | 79.46M | -72.96M | - | 18.50M | -20.69M | 5.52M | -23.11M |
| Shares Outstanding | - | - | - | - | - | - | 56.26M | 57.82M | 63.50M | 65.01M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -13.22M | -25.67M | -93.38M | -57.87M | -33.39M | -84.91M | -34.01M | -18.00M | -42.27M |
| Investing Cash Flow | 0 | -9.00K | -23.43M | 12.19M | 4.03M | -2.94M | -1.63M | -4.82M | -8.45M |
| Financing Cash Flow | 13.04M | 118.84M | 133.55M | 38.35M | 73.05M | -4.15M | 44.64M | 47.41M | 17.34M |
| Capital Expenditure | -0 | -9.00K | -345.00K | -815.00K | -393.00K | -1.62M | -473.00K | -1.47M | -3.44M |
| Free Cash Flow | -13.22M | -25.68M | -93.73M | -58.69M | -33.78M | -86.53M | -34.48M | -19.47M | -45.71M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 77.1% | - | - | 60.4% | 68.1% | 68.5% | 66.3% |
| Operating Margin % | - | - | -283.3% | -270.7% | -44.6% | -44.0% | -24.4% | -12.9% | -11.0% |
| Net Margin % | - | - | -257.8% | -288.3% | -47.0% | -50.1% | -30.5% | -18.9% | -17.4% |
| ROE % | 5.9% | -55.5% | -113.3% | 223.4% | - | -402.2% | 298.2% | -913.1% | 223.5% |
| ROCE % | 19.4% | -27.7% | -45.8% | -531.1% | - | -49.7% | -35.0% | -20.3% | -21.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Nantahala Capital Management, LLC | 8.48% | 5.60M | $49.75M |
| 2 | Blackrock Inc. | 7.33% | 4.84M | $42.99M |
| 3 | Braidwell LP | 4.78% | 3.16M | $28.02M |
| 4 | Frazier Life Sciences Management, L.P. | 3.98% | 2.63M | $23.36M |
| 5 | Perceptive Advisors Llc | 3.72% | 2.46M | $21.84M |
| 6 | Vanguard Capital Management LLC | 3.58% | 2.36M | $20.98M |
| 7 | Millennium Management Llc | 2.71% | 1.79M | $15.88M |
| 8 | State Street Corporation | 2.57% | 1.70M | $15.07M |
| 9 | Geode Capital Management, LLC | 2.44% | 1.61M | $14.28M |
| 10 | Stonepine Capital Management, LLC | 2.41% | 1.59M | $14.12M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EOLS
Insider Sale: See Remarks of $EOLS Sells 105,108 Shares - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQZjYxY2xFUHdtMGVSTDQ0Qk5WeGlBYlM1SGwxNUVUWGx4QkZTWE11SXd0cG5Cd0ltLXdTVF8xWk1VcWtheU1BZUl3N3JDS0RMcGtfZXlkMS1YOUVWdWpRc05RY2hmcWdtUGFEQTVzcFJLdjVUNmVXLWJ4OEg5RVNzMUNPbDNpdlVwY3dHWF…
Insider at Evolus (NASDAQ: EOLS) moves to sell nearly $1M in stock - Stock Titan
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxPeFY1YjVfaUJsYV9JMHEyUTVZNWZ4dVM4bkRUUERhMm9TdW9XUDRoVEd5Q0IyQmYwa0JTbkZmU0JvVUdYNENtWjFyMnVzMVVMTjJ3bWltbV9NTVVrN0gxaUk2S3hDSGk2cWRZTDBndzJoczNDQVg2TUxWTXZvckhCTmVUcTdEd2swOTVrSV…
Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPMVZJV04tMERQMVRLc2RGSm9zMFhaNzVnaWtlZFhCa0I0TERIUUluTkNicEVQTWFzejBhbXBKQUFFaG5YNjVMclY5SEI5bnVJOFo5cVdQaXAzcWE4NWZkSXVrczBLV1BzRjNQS2ZCaFlvTmRzZ3d4SFEzc25EaDU0ZmxRTkZzTWhpblBtSF…
EOLS Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9IWnBFdm1HTHRva1k1bkNZTV9vN1F3RzRXRXUtRTduTmhaWkNpMDhyYUxYazExV1JpLWFyUE1qcEtKNWVyeWt4amtnUVFNMHJWSkszUTFwV05zVS15aW9ERDRONXpoemk1WngzUkFHQ08tZWN4d3lxWkVn?oc=5" target="_blank">EOL…
Evolus president & CEO David Moatazedi sells $950,018 in shares By Investing.com - Investing.com Nigeria
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOMzBhc1ZjdEtxVEdzaFZNT2kxS1dpT3dZZHFkcmpKTnpOekFpU0VQT1JEeEpYVTk5NTZOd0tsWU5fQXNGN0Rla2NrdzI5UDAwRktTUERkUWNQcUE2S0pudEF3cmtNV1hWbkpxWThweDRiLTNYU2ZBbFkzZUtmaGliME1PaWpTZXBVMzdhMW…
Biotech Stocks At 52-Week Highs - RNXT +15%, EOLS, CRNX, APGE - RTTNews
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxONGZXUXNxSHJjWTJab1Bndjh3NGZwVWRDcVZSSjJsejhMVE5TUkg4dWVvWjZUTUR3VUhPUERZQW03bGFWWU83RWFyaFROSXVrb2cwbXRlazM0VHFROF85d3laZm96b3hNcVhFLXkxbHIyc0diajFjUGhDSnJuRkE0TDgxakVIekRMaFVnQ3…
EOLS — Frequently Asked Questions
What is the current share price of Evolus, Inc. (EOLS)?
As of 2026-09-07 16:24 PDT, Evolus, Inc. (EOLS) trades at $9.30 on NasdaqGM. Its 52-week range is $3.94 to $9.30.
What is the market capitalisation of EOLS?
Evolus, Inc. (EOLS) has a market capitalisation of $614.27M on NasdaqGM.
What is the P/E ratio of EOLS?
EOLS trades at a trailing price-to-earnings (P/E) ratio of -17.55. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -16.18.
Is EOLS a good stock to buy?
This page provides a data-driven analysis of Evolus, Inc. (EOLS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.